Incyte beats top-line and bottom-line estimates; updates FY25 outlook
Jul. 29, 2025 7:06 AM ET
By: Meghavi Singh, SA News Editor
- Incyte press release (NASDAQ: INCY): Q2 Non-GAAP EPS of $1.57 beats by $0.10.
- Revenue of $1.22B (+17.3% Y/Y) beats by $70M.
- Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million].
- Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y).
- Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million].
- 2025 Financial Guidance:
| Current
| Previous
| Jakafi net product revenues
| $3,000 - $3,050 million
| $2,950 - $3,000 million
| Opzelura net product revenues
| Unchanged
| $630 - $670 million
| Other oncology net product revenues(1)
| $500 - $520 million
| $415 - $455 million
| GAAP Cost of product revenues
| 8.0% - 9.0% of net product revenues
| 8.5% - 9.0% of net product revenues
| Non-GAAP Cost of product revenues(2)
| 7.0% - 8.0% of net product revenues
| 7.5% - 8.0% of net product revenues
| GAAP Research and development expenses
| $1,965 - $1,995 million
| $1,930 - $1,960 million
| Non-GAAP Research and development expenses(3)
| $1,815 - $1,840 million
| $1,780 - $1,805 million
| GAAP Selling, general and administrative expenses
| Unchanged
| $1,280 - $1,310 million
| Non-GAAP Selling, general and administrative expenses(3)
| Unchanged
| $1,160 - $1,185 million
|
|
